Laura Fogliatto

机构：Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre · ORCID：0000-0001-5011-192X

发表论文 111 篇 · 总被引 3247 次 · h-index 19

代表论文

• Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN (2023 · Blood · 被引 52)
• Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN (2025 · Blood · 被引 44)
• Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial (2025 · Journal of Clinical Oncology · 被引 22)
• CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma (2024 · Blood Advances · 被引 17)
• Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL (2025 · Blood Advances · 被引 11)
• Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population (2023 · Blood · 被引 11)